Cutting out the unnecessary: deprescribing antihypertensive treatments in patients at low cardiovascular risk - Top-Institutions - MDSpire

Cutting out the unnecessary: deprescribing antihypertensive treatments in patients at low cardiovascular risk

  • By

  • Matteo Lemoli

  • Claudia Agabiti Rosei

  • Maria Lorenza Muiesan

  • February 10, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Hypertension
    • Clinical Research

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Hypertension
    • Epidemiology

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Hypertension
    • Preventive Medicine

  • #4

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Cardiology
    • Hypertension
    • Clinical Trials

  • #5

    Imperial College London
    Imperial College London

    London, UK

    Key Differentiators

    • Cardiology
    • Hypertension
    • Public Health

Original Source(s)

Cutting out the unnecessary: deprescribing antihypertensive treatments in patients at low cardiovascular risk

  • by Matteo Lemoli, Claudia Agabiti Rosei, Maria Lorenza Muiesan

  • February 10, 2026

Related Content

Side Effects: They Googled It

Patients are mining Reddit and TikTok for symptom intel while you're not — and a small study calls it epistemic injustice. Different knowledge, mutually unrecognized. Maybe ask where they've been reading before you wave it off as anecdote.

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.